Can a pathological complete response of breast cancer after neoadjuvant chemotherapy be diagnosed by minimal invasive biopsy?

[1]  H. Kuerer,et al.  Comment on ‘Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques' , 2016, British Journal of Cancer.

[2]  H. Kuerer,et al.  Selective elimination of breast cancer surgery in exceptional responders: historical perspective and current trials , 2016, Breast Cancer Research.

[3]  A. Schneeweiss,et al.  Can Routine Imaging After Neoadjuvant Chemotherapy in Breast Cancer Predict Pathologic Complete Response? , 2016, Annals of Surgical Oncology.

[4]  G. Rauch,et al.  Diagnosis of pathological complete response to neoadjuvant chemotherapy in breast cancer by minimal invasive biopsy techniques , 2015, British Journal of Cancer.

[5]  L. Esserman,et al.  Standardization of pathologic evaluation and reporting of postneoadjuvant specimens in clinical trials of breast cancer: recommendations from an international working group , 2015, Modern Pathology.

[6]  Gideon Blumenthal,et al.  Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis , 2014, The Lancet.

[7]  S. Loibl,et al.  Surgical treatment of primary breast cancer in the neoadjuvant setting , 2014, The British journal of surgery.

[8]  M. Rezai,et al.  Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): a randomised phase 2 trial. , 2014, The Lancet. Oncology.

[9]  M. Bani,et al.  Evaluation of Newly Adapted Clip Marker System in Ultrasound-Guided Core Needle Biopsy for Suspicion of Breast Cancer. , 2013, Geburtshilfe und Frauenheilkunde.

[10]  A. Schneeweiss,et al.  Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  Les Irwig,et al.  Meta-analysis of magnetic resonance imaging in detecting residual breast cancer after neoadjuvant therapy. , 2013, Journal of the National Cancer Institute.

[12]  P. Fasching,et al.  Definition and impact of pathologic complete response on prognosis after neoadjuvant chemotherapy in various intrinsic breast cancer subtypes. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  A. Tutt,et al.  Recommendations from an International Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in Primary Breast Cancer , 2012, Annals of Surgical Oncology.

[14]  K. Jung,et al.  Comparison of mammography, sonography, MRI and clinical examination in patients with locally advanced or inflammatory breast cancer who underwent neoadjuvant chemotherapy. , 2011, The British journal of radiology.

[15]  William E Gillanders,et al.  Accuracy of ultrasonography and mammography in predicting pathologic response after neoadjuvant chemotherapy for breast cancer. , 2010, American journal of surgery.

[16]  Fang Fan.  Evaluation and Reporting of Breast Cancer after Neoadjuvant Chemotherapy , 2009 .

[17]  R. Kreienberg,et al.  First Revision of the German S3 Guideline ‘Diagnosis, Therapy, and Follow-Up of Breast Cancer’ , 2008, Breast Care.

[18]  S. Loibl,et al.  Intensified neoadjuvant chemotherapy in early-responding breast cancer: phase III randomized GeparTrio study. , 2008, Journal of the National Cancer Institute.

[19]  W. Woodward,et al.  Placement of radiopaque clips for tumor localization in patients undergoing neoadjuvant chemotherapy and breast conservation therapy , 2007, Cancer.

[20]  F. Vicini,et al.  Molecular classification system identifies invasive breast carcinoma patients who are most likely and those who are least likely to achieve a complete pathologic response after neoadjuvant chemotherapy , 2007, Cancer.

[21]  D. Tiezzi,et al.  HER-2, p53, p21 and hormonal receptors proteins expression as predictive factors of response and prognosis in locally advanced breast cancer treated with neoadjuvant docetaxel plus epirubicin combination , 2007, BMC Cancer.

[22]  Andreas Makris,et al.  Recommendations from an international expert panel on the use of neoadjuvant (primary) systemic treatment of operable breast cancer: an update. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  S. Singletary,et al.  Accuracy of Physical Examination, Ultrasonography, and Mammography in Predicting Residual Pathologic Tumor Size in Patients Treated With Neoadjuvant Chemotherapy , 2006, Annals of surgery.

[24]  Roman Rouzier,et al.  Gene expression profiles in paraffin-embedded core biopsy tissue predict response to chemotherapy in women with locally advanced breast cancer. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  W. Allum,et al.  Is surgery necessary after complete clinical remission following neoadjuvant chemotherapy for early breast cancer? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[26]  D. Wickerham,et al.  Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  M. Kaufmann,et al.  Histologische Regression des Mammakarzinoms nach primärer (neoadjuvanter) Chemotherapie , 1994 .

[28]  L. Schwartz,et al.  New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). , 2009, European journal of cancer.